Stock DFB HEALTHCARE ACQUISITIONS CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News DFB Healthcare Acquisitions Corp. Nasdaq

Equities

US23291E2081

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AdaptHealth Corp. to Participate in the BofA Securities 2024 Health Care Conference
BU
AdaptHealth's Shares Fall After Q1 Net Loss Misses Analysts' Forecast
MT
Earnings Flash (AHCO) ADAPTHEALTH Reports Q1 Revenue $792.5M, vs. Street Est of $769.9M
MT
AdaptHealth Corp. Announces First Quarter 2024 Results
BU
AdaptHealth Corp. Announces First Quarter 2024 Earnings Release Date and Conference Call
BU
AdaptHealth Names Suzanne Foster as CEO
MT
AdaptHealth Appoints Suzanne Foster as Chief Executive Officer
BU
UBS Adjusts AdaptHealth Price Target to $13 From $9, Maintains Buy Rating
MT
Deutsche Bank Adjusts AdaptHealth Price Target to $10 From $8, Maintains Hold Rating
MT
AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2023 Results and Provides Initial 2024 Outlook
AQ
AdaptHealth's Q4 Loss Widens, Revenue Rises; Provides 2024 Revenue Guidance; Shares Climb
MT
Earnings Flash (AHCO) ADAPTHEALTH Posts Q4 Revenue $858.2M, vs. Street Est of $825.5M
MT
UBS Trims AdaptHealth Price Target to $9 From $10, Maintains Buy Rating
MT
Peloton Equity Leads Growth Investment in OnPoint Healthcare Partners
AQ
AHCO DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages AdaptHealth Corp. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AHCO
NE
AHCO DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages AdaptHealth Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AHCO
NE
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages AdaptHealth Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AHCO
NE
UBS Adjusts AdaptHealth Price Target to $10 From $18, Maintains Buy Rating
MT
BofA Securities Downgrades AdaptHealth to Underperform From Neutral, Adjusts Price Target to $6.50 From $9.50
MT
AdaptHealth Facing Headwinds Due to Slower-Than-Expected Patient Transitions, BofA Says
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AHCO Stock
  4. Stock
  5. News DFB Healthcare Acquisitions Corp.